Cadrenal Therapeutics Inc. (CVKD)

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial


Robert LeBoyerMedia Inquiries
Senior Life Sciences Analyst
March 13, 2024
Report ID: 26590
Get Report
Refer to the full report for the price target, fundamental analysis, and rating.

Equity Research provided by Noble Capital Markets is available at no cost to Registered users of Channelchek.

Already Registered? Click the ‘Get Report’ button to login and view the research report.

Not a Member? Click ‘Join’ or ‘Get Report’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.


Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc.
Healthcare
Biotechnology
Ticker
CVKD
Current Price
$0.3899 -3.73%
Market Cap
$6.2M
Price Target
Refer to Report
Volume
158.0K
52wk Range
$0.36 - $3.14
Related Research Reports
4/12/2024

Tecarfarin Receives Orphan Drug Designation For Second Indication
Tecarfarin Receives Orphan Drug Designation For Second Indication (CVKD)
3/13/2024

FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial
FY2023 Reported With Continued Progress Toward The Phase 3 Tecarfarin Trial (CVKD)
2/1/2024

Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin
Peer-Reviewed Journal Reviews Uses of DOAC Drugs, Pointing To The Need For Tecarfarin (CVKD)
12/18/2023

Addressing Unmet Anticoagulation Needs In Orphan Populations
Addressing Unmet Anticoagulation Needs In Orphan Populations (CVKD)

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.